BOSTON – October 30, 2026 -- Medicilon presented Revolution Medicines, Inc. with its "Excellence in Client Partnership Award" after more than three years of joint work on pan-KRAS drug discovery, following the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib in metastatic pancreatic cancer.